Warrant exercises, gross Proceeds from Warrant Exercises Balance Sheet Location [Axis] Balance Sheet Location [Axis] Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Lease liabilities long-term Operating Lease, Liability, Noncurrent Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Licensing Agreements Licensing Agreements [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Right of use asset Operating Lease, Right-of-Use Asset Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Legal, accounting and other fees related to purchase agreement Deferred Offering Costs Income Statement Location Income Statement Location [Axis] Statistical Measurement Statistical Measurement [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Annual maintenance fee Cost, Maintenance DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Income Statement [Abstract] Income Statement [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Canceled/forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Entity Registrant Name Entity Registrant Name Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Additional potential grant funding Additional Potential Funding Related To Grant Award Additional Potential Funding Related To Grant Award Number Of Common Stock Warrants Exercised Number Of Common Stock Warrants Exercised Number Of Common Stock Warrants Exercised Other non-current assets Other Assets, Noncurrent Other Non Current Assets Other Noncurrent Assets [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended and Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Milestone payment paid in common stock Milestone Payments, Contingent Amount Milestone payments, contingent amount. Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Related Party Transaction [Axis] Related Party Transaction [Axis] Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Entity File Number Entity File Number Canceled/forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Amendment Flag Amendment Flag Business development Business Development Equity Components [Axis] Equity Components [Axis] Hammock Pharmaceuticals, Inc Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Total current assets Assets, Current Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Sale of Stock Sale of Stock [Domain] Milestone payments term Milestone Payments, Term Milestone Payments, Term Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Subsequent Event Type Subsequent Event Type [Domain] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Increase in number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease) Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Issuance of common stock from the exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Research and development Research and Development Expense [Member] Product and Service [Axis] Product and Service [Axis] Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Sale of Stock Sale of Stock [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition Business Acquisition [Axis] Weighted-average fair value of options granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Potential annual license maintenance fee, payments in year one Potential Annual License Maintenance Fee, Payments In Year One Potential Annual License Maintenance Fee, Payments In Year One MBI MBI [Member] MBI Grant, DARE-PTB1 Grant, DARE-PTB1 [Member] Grant, DARE-PTB1 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Equity Award Award Type [Domain] Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Local Phone Number Local Phone Number Assets Assets [Abstract] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Statement [Line Items] Statement [Line Items] Remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Cash and cash equivalents Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Accumulated deficit Retained Earnings [Member] Counterparty Name [Domain] Counterparty Name [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Type of Adoption [Domain] Accounting Standards Update [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Deferred license revenue Contract with Customer, Liability, Noncurrent Project [Domain] Project [Domain] Related Party Related Party [Axis] Licensed Product or Process for Vaginal or Urological Use Licensed Product or Process for Vaginal or Urological Use [Member] Licensed Product or Process for Vaginal or Urological Use Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Certain clinical and regulatory development milestone payments License Agreement Notice Period Of Termination License Agreement Notice Period Of Termination Title of 12(b) Security Title of 12(b) Security Total assets Assets Expiration Date Class Of Warrant Or Rights Warrants Expiration Date Class of warrant or rights warrants expiration date. Plan Name Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Number of operating segments Number of Operating Segments Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Initial term of license agreement License Agreement, Initial Term License Agreement, Initial Term Loss per common share - basic (in usd per share) Earnings Per Share, Basic 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. Document Type Document Type Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Unamortized stock-based compensation expense Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Grant, DARE-FRT1 Grant, DARE-FRT1 [Member] Grant, DARE-FRT1 Renewal term of operating lease Lessee, Operating Lease, Renewal Term Prepaid expenses Prepaid Expense, Current Unamortized costs related to legal, accounting, and other fees Deferred Offering Costs, Unamortized Portion Deferred Offering Costs, Unamortized Portion Contingent consideration, liability Business Combination, Contingent Consideration, Liability Total payment Research and Development Agreement, Commitment, Amount Research and Development Agreement, Commitment, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants. Cash paid to stockholders' representative Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Going Concern Going Concern [Policy Text Block] Going Concern Cash paid for measurement of operating lease liabilities Operating Lease, Payments Options to purchase number of outstanding shares of common stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Other receivables Other Receivables, Net, Current Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Loss per common share - diluted (in usd per share) Earnings Per Share, Diluted Commission percent Percentage Of Aggregate Commission Percentage of aggregate commission. Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current License agreement termination periodic discontinued sale of product License Agreement Termination Periodic Discontinued Sale Of Product License Agreement Termination Periodic Discontinued Sale Of Product Other non-current assets Increase Decrease In Other Non Current Assets And Deferred Charges Increase decrease in other non-current assets and deferred charges. Potential additional consideration payable Registration Payment Arrangement, Maximum Potential Consideration Project [Axis] Project [Axis] Purchase Agreement Purchase Agreement [Member] Purchase Agreement Subsequent Events Subsequent Events [Text Block] Plan Name Plan Name [Axis] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent CRADA CRADA [Member] CRADA Deemed dividend from trigger of down round provision feature Deemed Dividend From Trigger Of Round Down Provision Feature Deemed Dividend From Trigger Of Round Down Provision Feature Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Entity Small Business Entity Small Business Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Total liabilities and stockholders' equity Liabilities and Equity Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Commitments and Contingencies Commitments Disclosure [Text Block] Accounts payable Accounts Payable, Current Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forgiveness of Paycheck Protection Program note payable Forgiveness of Paycheck Protection Program Note Payable Forgiveness of Paycheck Protection Program Note Payable Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] ATM Equity Offering Program ATM Equity Offering Program [Member] ATM Equity Offering Program Notes payable including accrued interest Notes Payable, Current, Plus Accrued Interest Notes Payable, Current, Plus Accrued Interest Sales based milestones amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Accounts payable Increase (Decrease) in Accounts Payable Accumulated other comprehensive loss AOCI Attributable to Parent [Member] License fee to be paid upon contingency License Fee, To Be Paid Upon Contingency License Fee, To Be Paid Upon Contingency Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Net Loss Per Share Earnings Per Share [Text Block] Percentage of rights to inventions by employees under license agreement Percentage Of Rights To Inventions By Employees Under License Agreement Percentage of rights to inventions by employees under license agreement. Operating expenses Operating Expenses [Abstract] Business acquisition transaction value Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Entity Interactive Data Current Entity Interactive Data Current Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' equity. Minimum Minimum [Member] Document Period End Date Document Period End Date Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Stockholders Equity [Table] Stockholders Equity [Table] Stockholders' equity. Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance Sheet Location [Domain] Balance Sheet Location [Domain] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Square footage of office space Net Rentable Area Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Income Statement Location Income Statement Location [Domain] Class of Warrant or Right Class of Warrant or Right [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Entity Address, State or Province Entity Address, State or Province Property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses License agreement termination period due to performance failure License Agreement Termination Period Due To Performance Failure License agreement, termination period due to performance failure. Current liabilities Liabilities, Current [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues MilanaPharm MilanaPharm [Member] MilanaPharm [Member] General and administrative General and Administrative Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Trading Symbol Trading Symbol Earnings Per Share [Abstract] Earnings Per Share [Abstract] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Exercisable (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Net amount payable Milestone Payments, Contingent Amount Payable, Net Milestone Payments, Contingent Amount Payable, Net Stock-Based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Related Party Transaction [Domain] Related Party Transaction [Domain] Upfront license fee paid Upfront License Fee, Amount Paid Upfront License Fee, Amount Paid Accounting Policies [Abstract] Accounting Policies [Abstract] Asset acquisition, contingent consideration Asset Acquisition, Contingent Consideration Asset Acquisition, Contingent Consideration Warrants Expiring on February 15, 2023 Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Total operating lease liabilities Operating Lease, Liability Document Transition Report Document Transition Report Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Warrants Warrant [Member] Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, $0.0001 par value; 120,000,000 shares authorized; 83,944,119 shares issued and outstanding at March 31, 2022 and December 31, 2021 Issues shares Common Stock, Value, Issued Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies (Note 7) Commitments and Contingencies Subsequent Event [Table] Subsequent Event [Table] Leased Properties Lessee, Operating Leases [Text Block] Stock-based compensation expense Share-based Payment Arrangement, Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Entity Current Reporting Status Entity Current Reporting Status Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Receivables [Abstract] Receivables [Abstract] Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Grant Awards Grant Award [Text Block] Grant Award [Text Block] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] NICHD NICHD [Member] NICHD Working capital Working Capital Increase (Deficit) Working Capital Increase (Deficit) Counterparty Name [Axis] Counterparty Name [Axis] Legal Entity Legal Entity [Axis] Class of Warrant or Right Class of Warrant or Right [Axis] Cover [Abstract] First commercial sale amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Class of Stock [Axis] Class of Stock [Axis] Sale of stock, number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Current assets Assets, Current [Abstract] Shares underlying outstanding warrants (in shares) Class of Warrant or Right, Outstanding Royalty agreement term Royalty Agreement, Term Royalty Agreement, Term Loan under paycheck protection program Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Leases [Abstract] Shares of common stock for net proceeds Sale of Stock, Consideration Received on Transaction Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Entity [Domain] Common stock issued to microchips capital stock holders (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Accrued expenses Accrued Liabilities, Current 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Revenue from grant for notice of award Revenue from Contract with Customer, Excluding Assessed Tax Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Other cost Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Related Party Related Party [Domain] Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-based Payment Arrangement, Option, Activity [Table Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Employee Stock Option Stock options Share-based Payment Arrangement, Option [Member] Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Prepaid expenses Increase (Decrease) in Prepaid Expense Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Weighted average amortization period Weighted Average Amortization Period Weighted Average Amortization Period Incremental borrowing rate Lessee, Operating Lease, Discount Rate Obligation to purchase common stock Purchase Obligation Common stock Common stock Common Stock [Member] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Entity Address, Address Line Two Entity Address, Address Line Two Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Loss from operations Operating Income (Loss) Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] General and administrative General and Administrative Expense [Member] Entity Shell Company Entity Shell Company Current portion of lease liabilities Operating Lease, Liability, Current Strategic Agreements Collaborative Arrangement Disclosure [Text Block] Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Lincoln Park Lincoln Park [Member] Lincoln Park Total current liabilities Liabilities, Current Class of Stock [Domain] Class of Stock [Domain] Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Stock-based compensation Share-based Payment Arrangement, Noncash Expense Additional paid-in capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation Depreciation Annual percentage increase in outstanding number of common stock Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Current Fiscal Year End Date Current Fiscal Year End Date Accrued expenses Increase (Decrease) in Accrued Liabilities Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Milestone payments Research And Development Milestone Payment Research and development milestone payment. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate. Deferred grant funding Deferred Grant Funding Current Deferred Grant Funding Current Other income Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Statistical Measurement Statistical Measurement [Axis] Other receivables Increase (Decrease) in Other Receivables Total liabilities Liabilities Subsequent Event Subsequent Event [Member] Initial payment Grants Receivable Award Type Award Type [Axis] Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Warrant, exercise price, decrease (in usd per share) Warrant, Exercise Price, Decrease Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Operating lease, right-of-use asset, statement of financial position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Common stock, shares issued (in shares) Common Stock, Shares, Issued April 2021 At The Market Sales Agreement April 2021 At The Market Sales Agreement [Member] April 2021 At The Market Sales Agreement Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] License fees License fee License Fee License Fee Subsequent Event Type Subsequent Event Type [Axis] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Non-cash lease expenses Operating Lease, Cost Entity Address, City or Town Entity Address, City or Town Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Upfront license fee paid Upfront License Fee Paid Upfront License Fee Paid Gain on extinguishment of note payable Gain on extinguishment of notes payable and accrued interest Gain (Loss) on Extinguishment of Debt Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Amount awarded for grant Proceeds From Award Of Grant Proceeds From Award Of Grant Organon Organon [Member] Organon Business combination shares issued (in usd per share) Business Acquisition, Share Price Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Payment of additional consideration Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]